Related Experiment Video
Updated: Feb 22, 2026

Experimental Paradigm for Measuring the Effect of Induced Emotion on Grammar Learning
Published on: January 29, 2020
Implications of GLAGOV study
Stephen J Nicholls1, Rishi Puri
1aSouth Australian Health and Medical Research Institute bUniversity of Adelaide, Australia cQuébec Heart & Lung Institute, Québec, Canada dCleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio, USA.
Insights
Adding PCSK9 inhibition with evolocumab to statin therapy significantly reduces LDL-C and promotes regression of coronary atherosclerosis. This demonstrates a direct link between LDL-C reduction and improved cardiovascular health.
Area of Science:
- Cardiology
- Pharmacology
- Medical Research
Background:
- Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition is a new strategy for lowering low-density lipoprotein cholesterol (LDL-C).
- The effect of PCSK9 inhibition on coronary atherosclerosis in patients already on statin therapy was previously unknown.
Purpose of the Study:
- To evaluate the impact of PCSK9 inhibition on coronary atherosclerosis progression in statin-treated patients.
- To assess the relationship between LDL-C levels and coronary atherosclerosis regression.
Main Methods:
- The GLAGOV trial investigated the effect of evolocumab (a PCSK9 inhibitor) versus placebo.
- Participants were on at least moderate-intensity statin therapy.
- Coronary atherosclerosis progression was assessed in relation to LDL-C levels.
Main Results:
- Evolocumab significantly lowered LDL-C levels (36.6 mg/dl) compared to placebo (93.0 mg/dl).
- This LDL-C reduction was associated with significant regression of coronary atherosclerosis.
- A direct correlation was found between achieved LDL-C levels and the extent of disease regression.
Conclusions:
- Combining evolocumab with statin therapy leads to incremental plaque regression in patients with existing coronary artery disease.
- These findings offer a biological basis for the observed cardiovascular benefits of evolocumab.
- PCSK9 inhibition represents a valuable therapeutic option for managing coronary atherosclerosis.
Purpose Of Review:
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition has emerged as a novel approach to lowering levels of low-density lipoprotein cholesterol (LDL-C). The impact of PCSK9 inhibition in statin-treated patients on coronary atherosclerosis had remained unknown.
Recent Findings:
The GLAGOV trial compared the effect of the PCSK9 inhibitor, evolocumab, and placebo on progression of coronary atherosclerosis in patients treated with at least moderate intensity statin therapy. Predictable lowering of LDL-C with evolocumab (36.6 versus 93.0 mg/dl) associated with significant regression of coronary atherosclerosis. A direct relationship was observed between achieved LDL-C levels and disease progression.
Summary:
Addition of evolocumab to statin therapy produces incremental regression of plaque regression in patients with established coronary artery disease. This finding provides a biological rationale for the reported beneficial effects of evolocumab on cardiovascular events.
More Related Videos
09:27Using Eye Movements Recorded in the Visual World Paradigm to Explore the Online Processing of Spoken Language
Published on: October 13, 2018
07:36Eye Tracking During Visually Situated Language Comprehension: Flexibility and Limitations in Uncovering Visual Context Effects
Published on: November 30, 2018
Related Concept Videos
Statistical Significance
Confirmation Biases
Causes of Similarity-Dissimilarity Effect
Correspondence Bias
Cognitive Learning
E. C. Tolman's theory of purposive behavior emphasizes that much behavior is goal-directed. He argued that to understand behavior, we must look at the entire sequence of actions leading to a goal. For instance, high school students study hard, not just due to past reinforcement but also to achieve the goal of getting into a good college.
Tolman introduced the idea that behavior is influenced by...
Theory of Attribution II: Kelley's Covariation Theory